In our study, we evaluated TP53 mutation status at baseline from 15 patients with prior chemotherapy, either by tumour DNA sequencing or cfDNA sequencing and all were TP53 wild type (Fig. 1b). This evidence concerns the gene TP53 and neoplasm.